CSL plans to tap into its 106-years of experience to catapult Vifor’s iron deficiency and renal products business, unlocking additional scale and new use cases for its products in the short term, but the real story behind its $11.7 billion acquisition lies in the potential of the pair’s R&D portfolios.
Addressing investors and analysts in the company’s first major briefing on its strategy for the Vifor business since it announced the acquisition in December, CSL CEO Paul Perreault likened the Vifor business to where CSL was a decade ago.
Loading...
Yolanda Redrup is the co-editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
